Shopping Cart
Remove All
Your shopping cart is currently empty
Mirikizumab (LY3074828) is a humanized monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), modulating immune response by inhibiting IL-23 binding to IL-23R, used in studies of ulcerative colitis.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $213 | In Stock | In Stock | |
| 5 mg | $562 | In Stock | In Stock | |
| 10 mg | $893 | - | In Stock | |
| 25 mg | $1,320 | - | In Stock | |
| 50 mg | $1,780 | - | In Stock |
| Description | Mirikizumab (LY3074828) is a humanized monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), modulating immune response by inhibiting IL-23 binding to IL-23R, used in studies of ulcerative colitis. |
| In vitro | Mirikizumab binds IL-23 in humans and monkeys with high affinity, with Kd values of 21 pM and 55 pM, respectively. [1] |
| In vivo | Mirikizumab (4.4 pm-800 nM, 48 h) completely neutralizes IL-17A induced by human and cynocytic monkey IL-23 in mouse spleen cells with IC50 of 82 pM and 120 pM, respectively. [1] |
| Synonyms | LY3074828, LY 3074828 |
| Cas No. | 1884201-71-1 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.